2X1:ETR
Abivax SA
€97,45
arrow_downward
-0,36%(-0,35) 1D
7 Sep., 17:30:00 GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2X1...
Open
€98,65
High
€100,80
Low
€97,35
Mkt. cap
8,55 mjd
Avg. vol.
1,38 k
Volume
1,71 k
52-wk high
€137,40
52-wk low
€60,85
EPS
-€4,49
No. of employees
80
Open
€98,65
High
€100,80
Low
€97,35
Mkt. cap
8,55 mjd
Avg. vol.
1,38 k
Volume
1,71 k
52-wk high
€137,40
52-wk low
€60,85
EPS
-€4,49
No. of employees
80
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees80
Founded04 Des. 2013
Headquarters-
Sector-
Websiteabivax.com